Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
59 pending office actions • 41 clients • 55 examiners • 26 art units • 0 of 59 (0%) have an AI response strategy ready
McNeill PLLC has managed 1931 career applications in the Biotechnology & Pharmaceuticals technology area. The firm has a resolved allowance rate of 70.41 percent. Prosecution typically involves an average of 3.63 office actions per allowance.
There are 48 pending office actions currently active. The 70.41 percent allowance rate and 3.63 average office actions per allowance provide a baseline for the firm's performance across its 1931 career applications. This data reflects the firm's substantial involvement in the biotech sector and its current ongoing prosecution efforts as shown by the 48 pending actions.
Based on the USPTO statutory response window for each pending office action. 14 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 14 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 8 (14%) |
| §103 only | 9 (15%) |
| §112 only | 7 (12%) |
| Double-patenting only | 2 (3%) |
| Double-patenting + other | 14 (24%) |
| Multi-statute (no §101) | 19 (32%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HASAN, KHALEDA B | 2 | 59.4% | +49.5% |
| DEVI, SARVAMANGALA | 2 | 65.3% | +55.3% |
| HASTINGS, ALISON AZAR | 2 | 63.5% | +40.2% |
| HIBBERT, CATHERINE S | 2 | 58.9% | +48.8% |
| CHANDRAKUMAR, NIZAL S | 1 | 72.7% | +18.3% |
| FAN, WEIHUA | 1 | 83.4% | +12.6% |
| PACKARD, BENJAMIN J | 1 | 66.7% | +15.6% |
| AGGARWAL, SAHIL CHANDER | 1 | 100.0% | +0.0% |
| HUI, SAN MING R | 1 | 59.5% | +20.1% |
| KEOGH, MATTHEW R | 1 | 78.3% | +14.5% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19276658 | Stabilized Nucleic Acids Encoding Messenger Ribonucleic Acid (mRNA) | FAN, WEIHUA | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18248079 | CD19-Directed Chimeric Antigen Receptor Constructs | HAMA, JOANNE | 104d overdue |
| 17836265 | Modified Guide RNAs for Gene Editing | ARIETI, RUTH SOPHIA | 30d overdue |
| 17921128 | Glucocorticoid Receptor (GR) Modulators for Treating a SARS-COV-2 Virus | HAVLIN, ROBERT H | 23d overdue |
| 17637410 | BLOOD GENE BIOMARKERS TO DIAGNOSE AND PREDICT ACUTE REJECTION IN LIVER TRANSPLANT RECIPIENTS | MYERS, CARLA J | 2d overdue |
| 18844546 | Modulation of Protein Levels | KEOGH, MATTHEW R | 60d |
| 19571722 | Lamotrigine Salts, Co-Crystals, and Compositions | CHANDRAKUMAR, NIZAL S | — |
| 19100872 | Reduction of Signs of Skin Aging | PACKARD, BENJAMIN J | — |
| 18924880 | Abuse-Deterrent Pharmaceutical Composition with Aversion Properties | AGGARWAL, SAHIL CHANDER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18844546 | Modulation of Protein Levels | KEOGH, MATTHEW R | 60d |
| 19630254 | Compositions and Methods Comprising a TTR Guide RNA and a Polynucleotide Encoding an RNA-Guided DNA Binding Agent | HASAN, KHALEDA B | — |
| 19571722 | Lamotrigine Salts, Co-Crystals, and Compositions | CHANDRAKUMAR, NIZAL S | — |
| 19276658 | Stabilized Nucleic Acids Encoding Messenger Ribonucleic Acid (mRNA) | FAN, WEIHUA | — |
| 19100872 | Reduction of Signs of Skin Aging | PACKARD, BENJAMIN J | — |
| 18850107 | Novel Salt of GLP-1 Receptor Agonist Compound, Preparation Method Thereof and Pharmaceutical Composition Comprising Thereof | HUI, SAN MING R | — |
| 18640699 | Parabacteroides Goldsteinii to Treat or Prevent Inflammatory and AutoImmune Diseases | DEVI, SARVAMANGALA | — |
| 18683006 | 2,4-Dihydro-3H-1,2,4-Triazol-3-One P2X7 Antagonists | HASTINGS, ALISON AZAR | — |
| Art Unit | Apps |
|---|---|
| 1636 | 3 |
| 1645 | 3 |
| 1629 | 3 |
| 1627 | 3 |
| 1633 | 3 |
| 1625 | 2 |
| 1663 | 2 |
| 1682 | 2 |
| 1675 | 2 |
| 1658 | 2 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19630254 | Compositions and Methods Comprising a TTR Guide RNA and a Polynucleotide Encoding an RNA-Guided DNA Binding Agent | Intellia Therapeutics, Inc. | HASAN, KHALEDA B | 1636 | §103DP | Non-Final OA | — | Pending | Mar 26, 2026 |
| 19571722 | Lamotrigine Salts, Co-Crystals, and Compositions | Azurity Pharmaceuticals Ireland Limited | CHANDRAKUMAR, NIZAL S | 1625 | §103§112Other | Final Rejection | — | Pending | Mar 19, 2026 |
| 19276658 | Stabilized Nucleic Acids Encoding Messenger Ribonucleic Acid (mRNA) | Intellia Therapeutics, Inc. | FAN, WEIHUA | DP | Non-Final OA | — | Pending | Jul 22, 2025 | |
| 19100872 | Reduction of Signs of Skin Aging | Carbocode S.A. | PACKARD, BENJAMIN J | §101§102§112DP | Non-Final OA | — | Pending | Feb 03, 2025 | |
| 18924880 | Abuse-Deterrent Pharmaceutical Composition with Aversion Properties | Aardvark Therapeutics Inc. | AGGARWAL, SAHIL CHANDER | §102§103§112 | Non-Final OA | — | Pending | Oct 23, 2024 | |
| 18850107 | Novel Salt of GLP-1 Receptor Agonist Compound, Preparation Method Thereof and Pharmaceutical Composition Comprising Thereof | Ildong Pharmaceutical Co., Ltd. | HUI, SAN MING R | §103 | Non-Final OA | — | Pending | Sep 24, 2024 | |
| 18844546 | Modulation of Protein Levels | Carlsberg A/S | KEOGH, MATTHEW R | 1663 | §102§103§112 | Final Rejection | 60d | Pending | Sep 06, 2024 |
| 18782817 | Method for Using Gene Expression to Determine Prognosis of Prostate Cancer | Mdxhealth SA | HANEY, AMANDA MARIE | §101§103§112 | Non-Final OA | — | Pending | Jul 24, 2024 | |
| 18728193 | DETECTION AND LOCALIZATION OF INTERNAL BLEEDING | Cumberland Emerging Technologies, Inc. | LEWOCZKO, EVAN MICHAEL | §103 | Non-Final OA | — | Pending | Jul 11, 2024 | |
| 18724529 | Altering the Optical Properties of Fibres | Commonwealth Scientific And Industrial Research Organisation | KRUSE, DAVID H | 1663 | §102§103§112 | Non-Final OA | — | Pending | Jun 26, 2024 |
| 18739986 | AAV Vectors | Vigeneron GmbH | BLUMEL, BENJAMIN P | 1671 | §112 | Final Rejection | — | Pending | Jun 11, 2024 |
| 18716404 | Uses of Bicyclic Compounds for the Treatment of Diseases | Leonabio, Inc. | COPPINS, JANET L | §103§112DP | Non-Final OA | — | Pending | Jun 04, 2024 | |
| 18710370 | Formulations and Methods for Treating Symptoms of Menopause | Kindra Corporation | OLSON, ANDREA STEFFEL | §102§103§112DP | Non-Final OA | — | Pending | May 15, 2024 | |
| 18708367 | Gap Junction Modulators and Their Use for the Treatment of Age-Related Macular Degeneration | Breye Therapeutics Aps | KATAKAM, SUDHAKAR | §112 | Non-Final OA | — | Pending | May 08, 2024 | |
| 18640699 | Parabacteroides Goldsteinii to Treat or Prevent Inflammatory and AutoImmune Diseases | Joslin Diabetes Center | DEVI, SARVAMANGALA | 1645 | §102§112 | Non-Final OA | — | Pending | Apr 19, 2024 |
| 18702733 | CONDITION-ACTIVATABLE NUCLEIC ACID CONSTRUCTS AND THEIR USES FOR TREATING NEUROLOGICAL DISEASES | Switch Therapeutics Inc. | YU, DAVID TUYANG | §103§112DP | Non-Final OA | — | Pending | Apr 18, 2024 | |
| 18695940 | SOS1 Inhibitor With Pyrido-Fused Six-Membered Ring Structure | Haihe Biopharma Co., Ltd. | SCHMITT, MICHAEL J | 1629 | §102§112 | Non-Final OA | — | Pending | Mar 27, 2024 |
| 18611364 | ST2 ANTIGEN BINDING PROTEINS | Amgen, Inc. | MCCOLLUM, ANDREA K | §101§112Other | Non-Final OA | — | Pending | Mar 20, 2024 | |
| 18690358 | Hydroxamic Acid Compound Having ENPP1 Inhibitory Activity and Use Thereof | Haihe Biopharma Co., Ltd. | TOWNSLEY, SARA ELIZABETH | 1629 | §102§103§112Other | Non-Final OA | — | Pending | Mar 08, 2024 |
| 18683006 | 2,4-Dihydro-3H-1,2,4-Triazol-3-One P2X7 Antagonists | Breye Therapeutics Aps | HASTINGS, ALISON AZAR | 1627 | §103§112 | Final Rejection | — | Pending | Feb 12, 2024 |
| 18435117 | Compounds and Compositions for Selective Degradation of Engineered Proteins | Bristol-Myers Squibb Company | ISMAIL, REHANA | 1625 | §102§103§112 | Non-Final OA | — | Pending | Feb 07, 2024 |
| 18434621 | CONJUGATES COMPRISING COVALENT BINDERS FOR TARGETING INTRACELLULAR PROTEINS | Rayzebio, Inc. | MOSHER, ERIC PARKER | §101§102§103§112DP | Non-Final OA | — | Pending | Feb 06, 2024 | |
| 18431646 | CONJUGATES COMPRISING COVALENT BINDERS FOR TARGETING INTRACELLULAR KRAS G12C PROTEINS | Rayzebio, Inc. | MEJIAS, SAMANTHA LEE | §103§112 | Non-Final OA | — | Pending | Feb 02, 2024 | |
| 18431656 | CONJUGATES COMPRISING COVALENT BINDERS FOR TARGETING INTRACELLULAR PROTEINS | Rayzebio, Inc. | DONOHUE, SEAN R | §102§103DP | Non-Final OA | — | Pending | Feb 02, 2024 | |
| 18423804 | Methods, Systems, and Compositions for Diagnosing Transplant Rejection | The Scripps Research Institute | JONES, CHRISTINE MICHELLE | 1682 | §101§103§112DP | Non-Final OA | — | Pending | Jan 26, 2024 |
| 18577414 | Fetal Mesenchymal Stem Cells | Boost Pharma Aps | WESTON, ALYSSA G | 1633 | §101§102§103 | Final Rejection | — | Pending | Jan 08, 2024 |
| 18513964 | Methods for Reducing Risk of Onset of Acute Graft Versus Host Disease After Hematopoeitic Cell Transplantation | Csl Behring LLC | BEANE, RANDALL L | 1654 | §103 | Final Rejection | 70d | Pending | Nov 20, 2023 |
| 18510979 | Therapeutic Microvesicles of Probiotic Bacteria | BIOGAIA AB | HINES, JANA A | 1645 | §103 | Non-Final OA | — | Pending | Nov 16, 2023 |
| 18511869 | USE OF HER2-TARGETING ANTIBODY-DRUG CONJUGATE IN TREATMENT OF HER2-LOW EXPRESSING BREAST CANCER | Remegen Co., Ltd. | BUCCINI, MICHELLE CALLAHAN | 1675 | §103§112DP | Non-Final OA | — | Pending | Nov 16, 2023 |
| 18507778 | Compositions and Methods for Targeting Cancer Stem Cells | The General Hospital Corporation | COOK, LISA V | 1642 | §103§112DP | Non-Final OA | — | Pending | Nov 13, 2023 |
| 18557182 | COMBINATION OF BITTER RECEPTOR AGONIST AND GUT-SIGNALING COMPOUND | Aardvark Therapeutics, Inc. | HIBBERT, CATHERINE S | 1658 | §102§103§112 | Non-Final OA | — | Pending | Oct 25, 2023 |
| 18279612 | Compositions and Methods For Reducing Immune Intolerance | Tim Therapeutics, Inc. | KIM, YUNSOO | 1641 | §112Other | Non-Final OA | — | Pending | Aug 31, 2023 |
| 18456269 | Compositions and Methods for Treatment of Myotonic Dystrophy Type 1 with CRISPR/SACAS9 | Vertex Pharmaceuticals Incorporated | VIJAYARAGHAVAN, JAGAMYA NMN | 1633 | §103§112Other | Non-Final OA | — | Pending | Aug 25, 2023 |
| 18450966 | USE OF ANTIBODY-DRUG CONJUGATE TARGETING HER2 IN TREATMENT OF SPECIFIC BREAST CANCER | Remegen Co., Ltd. | PUTTLITZ, KARL J | 1646 | §103DP | Final Rejection | — | Pending | Aug 16, 2023 |
| 18264475 | Formulations of DR5 Binding Polypeptides | Inhibrx Biosciences, Inc. | CESARE, JOSEPH DAVID | 1675 | §112Other | Non-Final OA | 5d | Pending | Aug 07, 2023 |
| 18339665 | Compositions and Methods for Reducing HLA-A in a Cell | Intellia Therapeutics, Inc. | SPENCER, ANDREA LYNNE MORRIS | 1631 | §103§112 | Non-Final OA | — | Pending | Jun 22, 2023 |
| 18339930 | Compositions and Methods for Genetically Modifying CIITA in a Cell | Intellia Therapeutics, Inc. | SMALL, KATHERINE R | 1633 | §102§112 | Non-Final OA | — | Pending | Jun 22, 2023 |
| 18332335 | Polynucleotides, Compositions, and Methods for Genome Editing Involving Deamination | Intellia Therapeutics, Inc. | REGA, KYLE THOMAS | 1636 | §102§103§112 | Non-Final OA | — | Pending | Jun 09, 2023 |
| 18332390 | Compositions and Methods for Reducing MHC Class II in a Cell | Intellia Therapeutics, Inc. | KIM, TAEYOON | 1631 | §102§103§112 | Non-Final OA | — | Pending | Jun 09, 2023 |
| 18265063 | Aldehyde Dehydrogenase Inhibitors and Their Therapeutic Use | Cancer Research Technology Limited | HASTINGS, ALISON AZAR | 1627 | §103 | Non-Final OA | — | Pending | Jun 02, 2023 |
| 18323488 | Methods and Treatment for Complex Lymphatic Malformations | Avalo, Inc. | KOSTURKO, GEORGE W | 1621 | §103 | Final Rejection | 49d overdue | Pending | May 25, 2023 |
| 18253485 | Method for Treating Antibody-Mediated Rejection | Csl Behring GmbH | HIBBERT, CATHERINE S | 1658 | §103§112DP | Final Rejection | — | Pending | May 18, 2023 |
| 18248079 | CD19-Directed Chimeric Antigen Receptor Constructs | Sorrento Therapeutics, Inc. | HAMA, JOANNE | 1647 | §103§112 | Final Rejection | 104d overdue | Pending | Apr 06, 2023 |
| 18070908 | Compositions Derived from Placenta and Methods of Producing the Same | StimLabs, LLC | JOHNSON, KARA D | 1632 | §102DP | Final Rejection | 5d | Pending | Nov 29, 2022 |
| 17792976 | Cytokine Prodrugs Comprising a Cleavable Linker | Trutino Biosciences Inc. | STOICA, ELLY GERALD | 1647 | §112 | Final Rejection | — | Pending | Nov 07, 2022 |
| 17921128 | Glucocorticoid Receptor (GR) Modulators for Treating a SARS-COV-2 Virus | Avm Biotechnology, LLC | HAVLIN, ROBERT H | 1626 | §103§112Other | Final Rejection | 23d overdue | Pending | Oct 25, 2022 |
| 17845399 | Pharmaceutical Composition for Treatment or Prevention of Multiple Inflammatory disorders | Aardvark Therapeutics, Inc. | IVANOVA, SVETLANA M | 1627 | §103 | Non-Final OA | 60d overdue | Pending | Jun 21, 2022 |
| 17836265 | Modified Guide RNAs for Gene Editing | Intellia Therapeutics, Inc. | ARIETI, RUTH SOPHIA | 1635 | §102§103§112Other | Final Rejection | 30d overdue | Pending | Jun 09, 2022 |
| 17824450 | DISTANCE DOMINANT INTRAOCULAR LENS | Bausch & Lomb Incorporated | RIOS, GABRIELLA GISELLE BONO | 3774 | §103 | Non-Final OA | — | Pending | May 25, 2022 |
| 17777402 | Processes for the Preparation of Alpha-Hydroxy Esters via Grignard Coupling and Thiolation Reactions | Kemin Industries, Inc. | CARR, DEBORAH D | 1691 | §112 | Non-Final OA | 72d overdue | Pending | May 17, 2022 |
| 17735929 | Methods and Compositions for Directed Genome Editing | Intellia Therapeutics, Inc. | HASAN, KHALEDA B | 1636 | §103§112DP | Non-Final OA | — | Pending | May 03, 2022 |
| 17637410 | BLOOD GENE BIOMARKERS TO DIAGNOSE AND PREDICT ACUTE REJECTION IN LIVER TRANSPLANT RECIPIENTS | Northwestern University | MYERS, CARLA J | 1682 | §101§102§103§112 | Non-Final OA | 2d overdue | Pending | Feb 22, 2022 |
| 17542712 | Replacement of Cytotoxic Preconditioning Before Cellular Immunotherapy | Avm Biotechnology, LLC | SANG, HONG | 1646 | §112 | Final Rejection | 14d | Pending | Dec 06, 2021 |
| 17532363 | URINE BIOMARKERS | Exosome Diagnostics, Inc. | POHNERT, STEVEN C | 1683 | §101§103§112DP | Final Rejection | — | Pending | Nov 22, 2021 |
| 17612074 | Substituted 4-[5-(Benzofuran-2-yl)-1,2,4-Oxadiazol-3-yl]Benzoic Acid Compounds for Use in Therapy for Neuropathic Pain | King'S College London | DAHLIN, HEATHER RAQUEL | 1629 | §103DP | Final Rejection | 12d | Pending | Nov 17, 2021 |
| 17469665 | Compositions and Methods for Treatment of Duchenne Muscular Dystrophy | Vertex Pharmaceuticals Incorporated | TATGE, LEXUS MARC | 1600 | §103DP | Non-Final OA | — | Pending | Sep 08, 2021 |
| 17418458 | Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof | Inhibrx Biosciences, Inc. | EDGINGTONGIORDANO, FRANCESCA | 1643 | §103Other | Non-Final OA | 66d overdue | Pending | Jun 25, 2021 |
| 17107203 | VEGFR-2 TARGETING DNA VACCINE FOR COMBINATION THERAPY | Vaximm AG | DEVI, SARVAMANGALA | 1645 | DP | Final Rejection | — | Pending | Nov 30, 2020 |
| 15550951 | MATERIALS AND METHODS FOR TREATMENT OF HEMOGLOBINOPATHIES | William Marsh Rice University | CANDELARIA, JULIANA IRENE | 1600 | §103DP | Final Rejection | — | Pending | Aug 14, 2017 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial